Notwithstanding the benefit of ARBs’ safety profiles, a major meta-analysis available in JAMA Internal Medicine exposed that ACE inhibitors decrease all-cause mortality, cardiovascular mortality, and major cardiovascular events in patients with diabetes mellitus, but ARBs had no advantages in these outcomes. This evidence concerns the gene ACE and diabetes mellitus.